Titre :

Semisynthetic Pneumococcal Glycoconjugate Nanovaccine

Auteur(s) :

Prasanna, Maruthi [Auteur]
Unité en Sciences Biologiques et Biotechnologies de Nantes [US2B]
Universidade de Santiago de Compostela [Spain] [USC ]
Varela Calvino, Rubén [Auteur]
Universidade de Santiago de Compostela [Spain] [USC ]
Lambert, Annie [Auteur]
Unité en Sciences Biologiques et Biotechnologies de Nantes [US2B]
Arista Romero, Maria [Auteur]
Institut de Química Avançada de Catalunya [CSIC] = Instituto de Química Avanzada de Cataluña [CSIC] = Institute of Advanced Chemistry of Catalonia [CSIC] [IQAC [CSIC]]
Pujals, Sylvia [Auteur]
Institut de Química Avançada de Catalunya [CSIC] = Instituto de Química Avanzada de Cataluña [CSIC] = Institute of Advanced Chemistry of Catalonia [CSIC] [IQAC [CSIC]]
Trottein, François [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Camberlein, Emilie [Auteur]
Unité en Sciences Biologiques et Biotechnologies de Nantes [US2B]
Grandjean, Cyrille [Auteur]
Unité en Sciences Biologiques et Biotechnologies de Nantes [US2B]
Csaba, Noemi [Auteur]
Universidade de Santiago de Compostela [Spain] [USC ]

Titre de la revue :

Bioconjugate Chemistry

Pagination :

1563-1575

Éditeur :

American Chemical Society

Date de publication :

2023-09-11

ISSN :

1043-1802

Mot(s)-clé(s) en anglais :

Biopolymers
Glycoconjugate vaccine
Immunology
Rodent models
Vaccination
Pneumococcus

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Chimie

Résumé en anglais : [en]

Pneumococcal conjugate vaccines offer an excellent safety profile and high protection against the serotypes comprised in the vaccine. However, inclusion of protein antigens from Streptococcus pneumoniaecombined with potent ...
Lire la suite >Pneumococcal conjugate vaccines offer an excellent safety profile and high protection against the serotypes comprised in the vaccine. However, inclusion of protein antigens from Streptococcus pneumoniaecombined with potent adjuvants and a suitable delivery system are expected to both extend protection to serotype strains not represented in the formulation and stimulate a broader immune response, thus more effective in young children, elderly, and immunocompromised populations. Along this line, nanoparticle (NP) delivery systems can enhance the immunogenicity of antigens by protecting them from degradation and increasing their uptake by antigen-presenting cells, as well as offering co-delivery with adjuvants. We report herein the encapsulation of a semisynthetic glycoconjugate (GC) composed of a synthetic tetrasaccharide mimicking theS. pneumoniae serotype 14 capsular polysaccharide (CP14) linked to the Pneumococcal surface protein A (PsaA) using chitosan NPs (CNPs). These GC-loaded chitosan nanoparticles (GC-CNPs) were not toxic to human monocyte-derived dendritic cells (MoDCs), showed enhanced uptake, and displayed better immunostimulatory properties in comparison to the naked GC. A comparative study was carried out in mice to evaluate the immune response elicited by the glycoconjugate-administered subcutaneously (SC), where the GC-CNPs displayed 100-fold higher IgG response as compared with the group treated with nonencapsulated GC. Overall, the study demonstrates the potential of this chitosan-based nanovaccine for efficient delivery of glycoconjugate antigens.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Projet Européen :

European Commission, Education, Audiovisual and Culture Executive Agency (EACEA), under the Erasmus Mundus programme, “NanoFar: European Doctorate in Nanomedicine and Pharmaceutical Innovation” (project: 2015-01-C4)
INNOvation with GLYcans: new frontiers from synthesis to new biological targets

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Source :

Harvested from HAL